



Blood
2025



ISBT
PERTH
2025

PROGRAM BOOK

2025 Annual Scientific Meeting and ISBT Regional Congress

26 - 29 October

Perth Convention and Exhibition Centre

www.blood-isbt-2025.com

Blood 2025

- the combined Annual
Scientific Meeting of the:



ISBT Perth

- 36th Regional
Congress of the:



Sponsors

Platinum Sponsors

abbvie

Johnson & Johnson



Gold Sponsors



Silver Sponsors



Destination Sponsors

WESTERN
AUSTRALIA

BUSINESS
EVENTS
PERTH



PERTH CONVENTION AND
EXHIBITION CENTRE

Contents

Social Program	1
Ancillary Meetings	2
Program Sunday 26 October	3
Program Monday 27 October	11
Program Tuesday 28 October	23
Program Wednesday 29 October	33

Registration Desk

The registration desk is located on the Central Foyer of the Perth Convention and Exhibition Centre and will be open at the following times:

Sunday 26 October	0700-1900hrs
Monday 27 October	0730-1800hrs
Tuesday 28 October	0730-1800hrs
Wednesday 29 October	0800-1300hrs

Wi-Fi Code

Network: Blood-ISBT
Password: Perth2025

Meeting Managers

Email: blood@theconferencecompany.com

Telephone: 1800 193 405 (Australian Freephone)
+64 9 360 1240 (International)

Postal: Level 35, International Tower One,
100 Barangaroo Avenue, Sydney, 2000, NSW
Or PO Box 90040, Auckland 1142

**THE
CONFERENCE
COMPANY**

Social Program

Welcome Reception

Date: Sunday 26 October, 1800hrs – 1930hrs

Venue: Exhibition Hall, Perth Convention and Exhibition Centre

Dress code: Business casual attire

Join us for the welcome reception on Sunday evening in the Exhibition Hall after the first day of Blood ISBT! Connect with fellow attendees, meet the speakers, and enjoy a special cultural performance from the Middar Dance Group. This is the perfect opportunity to network and set the stage for an engaging and productive event.

Diamonds and Pearls: A Night of Western Australian Elegance

Date: Tuesday 28 October, 1900-midnight



Venue: Grand Ballroom, Crown Perth

Dress code: A touch of glamour, or interpret Diamonds and Pearls your way: diamond/pearl inspired accessories, or creative nods to WA's iconic pearl and diamond industries

Transport: Coaches will depart at the following times:
5:30pm PCEC and InterContinental, Novotel, Parmelia Hilton
6:10pm PCEC and InterContinental, Novotel, Parmelia Hilton, Mercure

The Blood ISBT 2025 dinner theme Diamonds and Pearls pays tribute to the dazzling treasures of Western Australia. From the glittering pink diamond mines of the Kimberley to the lustrous pearls of Broome's pristine waters, WA's rich heritage in luxury and natural beauty sets the stage for an unforgettable evening. Expect sparkling conversation, radiant company, and a touch of opulence as Blood and ISBT come together.



Ancillary Meetings

Saturday 25 October

THANZ Scientific Workshop	0900 - 1700	Room M3 & River View 4 (exhibition)	Attendance by registration only
ISBT Meetings	0900 - 1700	Room M1	Closed Meeting
HSANZ Advanced Trainee Workshop	1000 - 1630	Room M2	Attendance by registration only
Joint Presidents' Meeting	1200-1300	Room M10	Closed Meeting
ANZSBT Council Meeting	1300 - 1700	Room M11	Closed Meeting
HSANZ Council Meeting	1400 - 1700	Room M10	Closed Meeting

Sunday 26 October

ISBT Young Professionals Breakfast	0700 - 0830	River View 4	Attendance by registration only
RCPA Supervisor Accreditation Workshop	1215 - 1315	Room M2 & 3	Attendance by registration only
Transfusion Practitioners Forum	1215 - 1315	River View 4	Open to Members
THANZ Council Meeting	1215 - 1315	Room M11	Closed Meeting

Monday 27 October

Blood Cancer Forum	0700 - 0830	Room M11	Closed Meeting
Nurses Member Meeting	1215 - 1315	Room M2 & 3	Open to Members
THANZ AGM	1215 - 1315	River View 4	Open to Members
Harold Gunson Lunch	1215 - 1315	Room M8	Closed Meeting

Tuesday 28 October

Lymphoma and Related Diseases Registry Breakfast Meeting	0700 - 0815	Room M1	Open
World Thrombosis Day Walk and Breakfast	0700 - 0815	Room M6	Open
HSANZ AGM	1215 - 1315	River View 4	Open to Members
Apheresis Special Practice Network Meeting	1215 - 1315	Room M2 & 3	Open to Members
HOW Collaborative AGM	1215 - 1315	Room M11	Open to Members

Meeting Program

Sunday 26 October

At a Glance

0700-0830	ISBT Young Professionals Breakfast <i>River View 4</i>				
0830-1000	Welcome to Country, Opening and Combined Plenary: Future is now: Big data and disruptive technologies in haematology <i>Riverside Theatre</i>				
1000-1030	Morning Tea <i>Exhibition Hall</i>				
1030-1200	HSANZ, BMTSAA, and ANZSBT/ISBT Joint Symposium: Next level cell therapy now <i>Riverside Theatre</i> ANZSBT / ISBT and THANZ Joint Symposium: Critical care: Achieving haemostasis without thrombosis <i>BelleVue 1</i>		ANZSBT/ISBT Symposium: Inequities in transfusion <i>BelleVue 2</i>	Nurses Symposium: Patient-centred care <i>M2 and 3</i>	
1200-1330	Lunch <i>Exhibition Hall</i>				
Lunchtime sessions:	Abbott Lunch Symposia: Getting future-ready: Stepping into the new era of blood and plasma screening <i>BelleVue 1</i>		RCPA Supervisor Accreditation Workshop <i>M2 and 3</i>	Transfusion Practitioners Forum <i>River View 4</i>	1245-1325: BMTSAA Lunchtime Symposium: Cell and tissue therapy <i>M1</i>
1215-1315	Grifols Lunch Symposia: Restoring pre-transfusion test reliability: sCD38 against anti-CD38 <i>BelleVue 2</i>				
1330-1425	Barry Firkin Oration: From bench to bedside and back again <i>Riverside Theatre</i> Ross Baker				
1430-1600	HSANZ Symposium: Improving outcomes in Indolent B cell malignancies <i>Riverside Theatre</i>	ANZSBT / ISBT Symposium: Platelet power! Evidence-based guidance and current clinical challenges <i>BelleVue 1</i> ANZSBT / ISBT Symposium: Should haemovigilance start with the impact of donor factors on product quality? <i>BelleVue 2</i>	THANZ Free Communications: Diagnosis and management of bleeding <i>River View 4</i>	Nurses: Free communications <i>1 M2 and 3</i>	BMTSAA Symposium <i>M1</i>
1600-1630	Afternoon Tea <i>Exhibition Hall</i>				
1630-1800	HSANZ Symposium: Can we predict or prevent acute leukaemia? <i>Riverside Theatre</i> (Kindly sponsored by Pfizer)	ANZSBT / ISBT Symposium: There's nothing positive about a positive antibody screen?! <i>BelleVue 1</i> ANZSBT / ISBT Symposium: Enhancing transfusion: From audit to implementation of best practice <i>BelleVue 2</i>	THANZ Symposium: Immune attack: TTP and APS <i>River View 4</i>	Nurses Symposium: Transplant and cellular therapies <i>M2 and 3</i>	BMTSAA Free Communications and Posters <i>M1</i>
1800-1930	Welcome Reception <i>Exhibition Hall</i>				
1930-late (pre-registration required)	AbbVie Dinner Symposia: International perspectives in CLL and DLBCL: The evolving landscape <i>M8</i> Gilead Dinner Symposia: Practical considerations for integrating CAR T into clinical practice for lymphoma <i>Offsite - The Ritz Carton</i>				

Sunday 26 October

0830-1000	Welcome to Country, Opening and Combined Plenary: Future is now: Big data and disruptive technologies in haematology <i>Chairs: Matthew Wright, Anastazia Keegan, Dominic Pepperell and Pierre Tiberghien</i>	Riverside Theatre
0830	Welcome to Country	
0900	AI in haematology	Claudia Haferlach
0920	Precision transfusion medicine from large vein to vein databases	Michael Busch <i>(Kindly supported by Roche)</i>
0940	Engineering the future of thrombosis management	Arnold Ju
1000-1030	Morning Tea	Exhibition Hall
1030-1200	HSANZ, BMTSAA, and ANZSBT/ISBT Joint Symposium: Next level cell therapy now <i>Chairs: Andrea Henden and Duncan Purtill</i>	Riverside Theatre
1030	GVHD prophylaxis: Lessons from the CAST study	David Curtis
1100	Precision targeted engineering of CarT cells	Phil Darcy
1130	Optimising your carT program	Mickey Koh
1030-1200	ANZSBT / ISBT and THANZ Joint Symposium: Critical care: Achieving haemostasis without thrombosis <i>Chairs: Anastazia Keegan and Dominic Pepperell</i>	BelleVue 1
1030	Chilled Platelet Study (CHIPS) in bleeding patients undergoing complex cardiothoracic surgery	Philip Spinella
1100	Left ventricular assist devices and anticoagulation: TTR matters	Jean Connors
1130	Thrombotic response in mechanical circulatory support	Anna Waterhouse
1030-1200	ANZSBT / ISBT Symposium: Inequities in transfusion <i>Chairs: Thierry Burnouf and Jenny White</i>	BelleVue 2
1030	Global inequities in blood supply and safety	Yuyun Maryuningsih
1100	Blood transfusion safety in Africa	Marion Vermeulen
1130	Delivering blood everywhere	Martin Smid
1030-1200	Nurses Symposium: Patient-centred care <i>Chairs: Andrew Steele and Gemma White</i>	M2 and 3
1030	Opening comments for Nursing stream	Andrew Steele

...continued overleaf

1040	Remote monitoring: Enhancing safety, symptom management, and patient engagement	Mary Steinbach
1110	Nursing leading change and equity in patient-centred care	Karen Strickland
1140	Modified Immune-effector Cell-associated Encephalopathy (ICE) scores	Ty Simpson

1200-1330	Lunch	Exhibition Hall
1215-1315	Abbott Lunch Symposia: Getting future-ready: Stepping into the new era of blood and plasma screening <i>Speaker: Ramune Sepetiene</i> <i>Pre-registration required</i>	BelleVue 1
1215-1315	Grifols Lunch Symposia: Restoring pre-transfusion test reliability: sCD38 against anti-CD38 <i>Chair: Xiaomei Zhu</i> <i>Speakers: Ariane Caesar, Annette Le Viellez</i> <i>Pre-registration required</i>	BelleVue 2
1215-1315	RCPA Supervisor Accreditation Workshop	M2 and 3
1200 - 1300	Transfusion Practitioners Forum	River View 4

1245-1325	BMTSAA Lunchtime Symposium: Cell and tissue therapy <i>Chairs: Celeste Hill and Ayse Mouminoglu</i>	M1
1245	Cell and tissue therapies WA	Zlatibor Velickovic
1305	Onboarding of CAR-T sites to supply leukapheresis materials for manufacturing of CAR-T products	Mark Dickson

1330-1425	Barry Firkin Oration: From bench to bedside and back again <i>Chair: James McFadyen</i>	Riverside Theatre
1330	Barry Firkin Oration: From bench to bedside and back again	Ross Baker

1430-1600	HSANZ Symposium: Improving outcomes in Indolent B cell malignancies <i>Chairs: Chan Cheah and Anna Johnston</i>	Riverside Theatre
1430	Navigating firstline treatment options in CLL	Matthew S. Davids <i>(Kindly supported by AbbVie)</i>
1500	Approach to relapsed follicular lymphoma	Laurie Sehn
1530	Novel immunotherapy for patients with indolent lymphoma	Sattva Neelapu <i>(Kindly supported by Gilead)</i>

...continued overleaf

1430-1600	ANZSBT / ISBT Symposium: Platelet power! Evidence-based guidance and current clinical challenges <i>Chairs: Satyam Arora and Philip Crispin</i>	BelleVue 1
1430	AABB/ICTM guidelines for platelet transfusion: How do I put this into practice?	Aaron Hess
1500	Monitoring prophylactic platelet transfusion response in acute leukemia patients	Priti Elhence
1515	Prevalence and predictors of platelet refractoriness in multiple transfusion requiring adult haematology inpatients: A prospective follow-up study	Aryabhatta Sadhu
1530	Efficacy of low dose prophylactic single donor platelet (SDP) transfusion in adult oncology patients with thrombocytopenia- A prospective study from a tertiary care oncology centre	Priti Desai
1545	A 10-year audit of platelet transfusion practice to monitor transfusion trigger thresholds over time	Christine Akers
1430-1600	ANZSBT / ISBT Symposium: Should haemovigilance start with the impact of donor factors on product quality? <i>Chairs: Alison Badger and Christian Erikstrup</i>	BelleVue 2
1430	Studying donor factors can help us precisely match the right donors to the right recipients	Jason Acker
1500	Study of effect of blood donor characteristics and component processing methods on platelet derived microparticles using flowcytometric and proteomic approach and clinical implications.	Amita Radhakrishnan Nair
1515	How cell salvage influences blood rheology and biophysical properties of erythrocytes	Michael Simmonds
1530	Examining the effect of blood donor sex and a blood processing method on potential transfusion outcomes: Could washing red cell components lower transfusion-related immunomodulation?	Joanne Tan
1545	Analysing the quality of blood products, a cohort study for Ugandan donors with diabetes	Waiswa Moses
1430-1600	THANZ Free Communications: Diagnosis and management of bleeding <i>Chairs: Jennifer Curnow and Carly George</i>	River View 4
1430	Study of tranexamic acid on post-tonsillectomy haemorrhage (STOP) pilot trial	Kate Wheadon
1445	Investigating the use of flow cytometry for the assessment of platelet dense granule disorders	David Connor

...continued overleaf

1500	Prospective cohort study on paediatric and adult haemophilia A patients correlating emicizumab levels and global coagulation assays with clinical experience	Stephanie P'Ng
1515	Acquired haemophilia A: Current treatment and outcomes with the advent of emicizumab therapy	Vicki Lee
1530	Utilising viscoelastography for the assessment of platelet function in thrombocytopenia	David Connor
1545	Congenital factor XIII deficiency: A disease not to be forgotten - real world experience from Malaysia	Andy Sing Ong Tang

1430-1600	Nurses: Free communications 1 <i>Chair: Rajeena George and Therese Thompson</i>	M2 and 3
1430	The importance of advanced practice nurses in standardised early palliative care for patients with aggressive haematological malignancies	Emily Bramstedt
1448	The evolution of a nurse led tele-support service (TSS) – utilising patient-family centred approach to provide comprehensive care to Bone Marrow Failure Syndromes (BMFS) community via case management conceptional framework	Mei Ling Yeh
1506	Evaluating central venous access device performance in patients with haematological cancers at four Victorian comprehensive cancer centre alliance clinical partner organisations: A multi-site cohort study	Kerrie Curtis
1524	Haematology and emergency nurses' experience and insights when assessing patients for neutropenic sepsis	Christine Mackey
1542	Bringing haematology home: The evolution of home-based cancer services at Epworth Healthcare	Agnes Nadine Friginal

1430-1600	BMTSAA Symposium <i>Chairs: Cheryl Hutchins and Michael Swain</i>	M1
1430	Translating immunobiology of haploidentical transplantation into clinical practice	Shanti Ramachandran
1500	Recent CAR-T trials in lymphoma	Katharine Lewis
1530	Review adult allogeneic TX and cell therapy	Duncan Purtill

1600-1630	Afternoon Tea	Exhibition Hall
------------------	----------------------	------------------------

1630-1800	HSANZ Symposium: Can we predict or prevent acute leukaemia? <i>(Kindly sponsored by Pfizer)</i> <i>Chairs: Carolyn Grove and Andrew Guirguis</i>	Riverside Theatre
------------------	---	--------------------------

...continued overleaf

1630	Can we prevent myeloid malignancies?	George Vassiliou
1700	Can we predict/prevent childhood ALL	Claudia Haferlach
1730	Predicting and intervening in AML relapse	Sun Loo

1630-1800	ANZSBT / ISBT Symposium: There's nothing positive about a positive antibody screen?! <i>Chairs: Nicole Thornton and Annette Le Vieillez</i>	BelleVue 1
1630	Approach to investigating panreactive antibodies	Jill Storry
1700	Assessing the risk of red blood cell alloimmunisation post-transfusion in patients receiving daratumumab in an Australian context	Amanda Goh
1715	Demystifying Anti-P1 antibodies - insights from a case series	Gayathiri Kaduveti Chellaiya
1730	Reduction in alloimmunisation and transfusion requirements in myeloid neoplasm patients receiving Rhesus and Kell phenotype-matched red blood cells	Michaela Spooner
1745	Blood group profiles for Australian blood donors with country of birth from South Asia and the Middle East	Sandra Sowah

1630-1800	ANZSBT / ISBT Symposium: Enhancing transfusion: From audit to implementation of best practice <i>Chairs: Rebecca McLean and Thierry Burnouf</i>	BelleVue 2
1630	Hospital level audits and surveys - challenges and benefits	Clare O'Reilly
1700	A questionnaire-based tool to analyse patient-reported experience during transfusion of blood and blood products in a hospital-based setting	Anila Mathan
1715	The most significant improvement in health in decades: How the development of a patient blood management program in Western Australia leads to 2024 WHO world guidelines for PBM implementation	Michael Leahy
1730	Impact of an institutionalized maximum surgical blood ordering schedule on red cell concentrate usage and stock management at a tertiary care women's hospital in Sri Lanka	Udeshika Sarathchandra Weerabaddana
1745	From manual review to meaningful insight: Improving the haemovigilance process in NSW	Rachel O'Neill

1630-1800	THANZ Symposium: Immune attack: TTP and APS <i>Chairs: Grace Gilmore and Danny Hsu</i>	River View 4
1630	Open or closed? Understanding the molecular mechanisms and clinical implications of ADAMTS13's conformation	Karen Vanhoorelbeke

...continued overleaf


1700	Life after acute TTP: Management of relapse risk and long-term complications	Katerina Pavenski
1730	Are we neglecting platelets in antiphospholipid syndrome?	Ibrahim Tohidi-Esfahani

1630-1800	Nurses Symposium: Transplant and cellular therapies <i>Chairs: Clair Scott and Ty Simpson</i>	M2 and 3
1630-1645	Infections post cellular therapies	Benjamin Joseph
1645-1700	Cytotoxic T lymphocytes treatment for post-transplant infections	Rajiv Khanna
1700-1715	CAR-T: Where are we now and where are we heading?	Safia Belbachir
1715-1730	Ambulatory cancer care service - FSH experience: Autologous and CAR-T cell therapy	Laura Pracilio
1730-1745	Long-term follow-up care after allogeneic transplant: Nurse-led NP and CNC clinic	Teresa Garcia

1630-1800	BMTSAA Free Communications and Poster <i>Chair: Gail Lazzaro and Rosanna Soares Mendes</i>	M1
1630	High platelet concentrations impair viable CD34+ cell recovery from autologous haemopoietic progenitor cells harvests: Investigating cause and effect	Loretta Huckstepp
1645	Intracellular Adenosine Triphosphate (iATP) is an early quantitative cell proliferation and potency marker for reducing transplant timeline	Jim Tiao
1700	A retrospective comparison of relapse rates and chronic graft versus host disease in patients undergoing matched unrelated allogeneic stem cell transplant with and without anti-thymoglobulin	Christopher McKinnely
Poster 1	Safe relocation of a cellular therapy laboratory: NSW Health Pathology-Liverpool Hospital experience	Vinita Agawal
Poster 2	From challenges to accreditation: The Hudson Institute Cell Therapies' (HICT) journey toward NATA recognition for peripheral blood stem cell autografts	Siow Chan
Poster 3	Anti-GBM renal disease occurring post-COVID infection in the setting of graft vs. host disease post allograft	Julian Cooney
Poster 4	Cryopreservation following overnight HPC(A) storage	Natasha McVeigh
Poster 5	Post-transplant early and late effects of fresh versus thawed vCD34 dose	Linda Welschinger
Poster 6	High efficacy of stem cell mobilization with reduced dose etoposide	Yea Bing Tham

...continued overleaf

1800-1930	Welcome Reception	Exhibition Hall
1930-2030	AbbVie Dinner Symposia: International perspectives in CLL and DLBCL: The evolving landscape <i>Speakers: Ghassan Zammar, Matthew Davids, Chan Cheah, Kat Lewis</i> <i>Pre-registration required</i>	M8
1930-till late	Gilead Dinner Symposia: Practical considerations for integrating CAR T into clinical practice for lymphoma <i>Chair: Duncan Purtill</i> <i>Speakers: Sattva Neelapu, Laurie Sehn</i> <i>Pre-registration required</i>	Offsite - The Ritz Carlton



0700-0815 (pre-registration required)	AstraZeneca Breakfast Symposia: Navigating the complexities of choice in the treatment of first-Line CLL <i>River View 4</i>			
	MRDR / Johnson & Johnson Breakfast Symposia: Real world experience and outcomes with novel immunotherapies in multiple myeloma <i>River View 5</i>			
0830-1000	HSANZ Free Communications: Low-grade lymphoma <i>Riverside Theatre</i>	ANZSBT Presidential Symposium <i>BelleVue 1</i>	THANZ Symposium: Adversity in anticoagulation <i>River View 4</i>	Nurses Symposium: Regional and remote <i>M2 and 3</i> (Kindly sponsored by BeOne Medicine)
	HSANZ Free Communications: Myeloma therapeutics <i>M1</i>			
	HSANZ Free Communications: Myeloid mutations, MDS and AML <i>River View 5</i> (Kindly sponsored by Astellas)			
	HSANZ Free Communications: Bone marrow transplant <i>M6</i>			
1000-1030	Morning Tea <i>Exhibition Hall</i>			
1030-1200	HSANZ Presidential Symposium <i>Riverside Theatre</i>	ANZSBT / ISBT Symposium: Close contact: Blood, risk and the invisible exchange <i>River View 5</i>	THANZ Presidential Symposium: From bench to bedside - developing novel targets/therapies <i>River View 4</i>	Nurses Free Communications: 2 <i>M2 and 3</i>
		ANZSBT / ISBT Symposium: Transfusion: The cornerstone of supportive care <i>BelleVue 1</i>		
		ANZSBT / ISBT Symposium: The search for the utopian donor <i>BelleVue 2</i>		
1200-1330	Lunch <i>Exhibition Hall</i>			
Lunchtime sessions:	Grifols Lunch Symposia: Navigating arboviral threats to blood safety <i>BelleVue 2</i>	How to get your paper published <i>M1</i>	THANZ AGM <i>River View 4</i>	Nurses Members Meeting <i>M2 and 3</i>
1215-1315	Werfen Lunch Symposia: From insight to action: Leading change in transfusion practice <i>BelleVue 1</i>			
1330-1425	Ruth Sanger Oration: Immunogenetics – expanding the horizon for transplantation and transfusion? <i>Riverside Theatre Rhonda Holdsworth</i>			
1430-1600	HSANZ Symposium: Myeloma: Moving immunotherapy into the mainstream <i>Riverside Theatre</i>	ANZSBT / ISBT Symposium: Plasma...but not as you know it! <i>BelleVue 1</i>	THANZ Symposium: Paediatric haemostasis <i>River View 4</i> (Kindly sponsored by Novartis)	Nurses Symposium: Novel therapies <i>M2 and 3</i>
	HSANZ Symposium: New trends and new tricks in transplantation <i>River View 5</i> (Kindly sponsored by AstraZeneca)			
	HSANZ Free Communications: Myeloproliferative neoplasms <i>M1</i> (Kindly sponsored by Incyte)	ANZSBT / ISBT Symposium: Transforming transfusion research <i>BelleVue 2</i>	THANZ Free Communications: Thrombosis and anticoagulation <i>M8</i> (Kindly sponsored by Werfen)	
	HSANZ Free Communications: Lymphoid malignancy: Basic science <i>M6</i>			
1600-1630	Afternoon Tea <i>Exhibition Hall</i>			
1630-1800	HSANZ Symposium: Making a difference in adult ALL <i>Riverside Theatre</i> (Kindly sponsored by Amgen)	ANZSBT / ISBT Symposium: Change: For better or worse? <i>River View 5</i>	THANZ Symposium: VWF: From physiology to phenotype <i>River View 4</i>	ANZSBT/ISBT Symposium: Clinical: Patient blood management in action <i>M6</i>
		ANZSBT / ISBT Symposium: Laboratory assessment of platelet immunobiology <i>BelleVue 1</i>	HSANZ / Nurses Joint Symposium: Burnout in health professionals: Understanding and addressing the challenge <i>M2 and 3</i>	
		ANZSBT/ISBT Symposium: Innovative manufacturing techniques for novel blood components of the future <i>BelleVue 2</i>		
1800-1930	Poster Viewing <i>Exhibition Hall</i>			
1830-1915 (ticket required to attend - places limited)	HSANZ Masterclass 1: HR Myeloma, defining and treating an area of unmet need <i>Gordon Cook M1</i>			
	HSANZ Masterclass 2: Frontline therapy of DLBCL <i>Laurie Sehn M6</i>			
	HSANZ Masterclass 3: Can we prevent blood cancer? <i>Claudia Haferlach and George Vassiliou M8</i>			
	Nurses Masterclass: CRS and ICANS in oncology nursing: Advanced assessment and management for immune effector therapies <i>Mary Steinbach M11</i>			
1930-2100 (pre-registration required)	GSK Dinner Symposia: Anaemia in focus: Evolving strategies in myelofibrosis management <i>Offsite - The Mark</i>			

Monday 27 October

0700-0815	AstraZeneca Breakfast Symposia: Navigating the complexities of choice in the treatment of first-Line CLL <i>Chair: Chan Cheah; Speaker: John Seymour</i> <i>Pre-registration required</i>	River View 4
0700-0815	MRDR / Johnson & Johnson Breakfast Symposia: Real world experience and outcomes with novel immunotherapies in multiple myeloma <i>Chair: Andrew Spencer</i> <i>Speakers: Gordon Cook, Tom Martin</i> <i>Pre-registration required</i>	River View 5

0830 - 1000	HSANZ Free Communications: Low-grade lymphoma <i>Chairs: Melita Cirillo and Sumita Ratnasingham</i>	Riverside Theatre
0830	Interim analysis of the umbrella Bayesian Optimal Phase II TOP-FLOR trial using rituximab, golcadomide +/- nivolumab in the treatment of newly-diagnosed follicular Lymphoma: An investigator initiated study	Eliza Hawkes
0845	Epcoritamab monotherapy demonstrates deep and durable responses at 3-year follow-up in patients with relapsed/refractory follicular lymphoma	Chan Cheah
0900	Synergistic effect of a Bcl-2 inhibitor and anti-CD20 monoclonal antibody in multiply relapsed/refractory Waldenström Macroglobulinaemia - a case series	Angeline Audrey Achola Josiah
0915	GoldiLox: First experience of safety and activity of two dosing strategies of pirtobrutinib and glofitamab for mantle cell lymphoma in patients previously treated with BTK inhibitors - an ALLG study	Adrian Minson
0930	Glofitamab in patients with heavily pretreated relapsed/refractory (R/R) Mantle cell lymphoma (MCL): Subgroup results from a phase I/II study (NP30179/NCT03075696)	Michael Dickinson
0945	Efficacy of rituximab-bendamustine with or without acalabrutinib in patients with untreated, high-risk mantle cell lymphoma: An analysis of the phase 3 ECHO trial	Chan Cheah

0830 - 1000	HSANZ Free Communications: Myeloma therapeutics <i>Chairs: Stephanie Lam and Nicole Wong Doo</i>	M1
0830	Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1	Hang Quach
0845	Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DvD) in relapsed/refractory multiple myeloma: Overall survival analysis and updated efficacy outcomes of DREAMM-7 trial	P Joy Ho

...continued overleaf

0900	Romosozumab for patients with multiple myeloma with skeletal events despite bisphosphonates	Betty Gration
0915	First-line VRd, Rd, and VCD in elderly transplant ineligible myeloma patients: Comparison of outcomes using the ANZ Myeloma and Related Diseases Registry	Sarah Zhao
0930	Regional trends in first-line myeloma treatment: Real world results from the Australian and New Zealand and Asia-Pacific myeloma and related diseases registries	Andrew Spencer
0945	New Zealand multiple myeloma patients demonstrate inferior outcomes when compared to Australia counterparts – a retrospective cohort study from the Myeloma and Related Diseases Registry (MRDR).	Jian Li

0830 - 1000	HSANZ Free Communications: Myeloid mutations, MDS and AML (Kindly sponsored by Astellas) Chairs: Simon Kavanagh and Peter Tan	River View 5
0830	Measuring unmet needs, biological features and bleeding phenotype in patients with inherited predisposition to myeloid neoplasms	Ahmad Alcheikh
0845	Evaluating a multidisciplinary model of care for inherited bone marrow failure and predisposition to haematological malignancy	Lucy Fox
0900	The genomic landscape of DDX41 variation identified through clinical sequencing in Australia	Celestine Wells
0915	Evaluating the role of morphology, immunophenotyping, and karyotyping in NPM1 MRD surveillance in acute myeloid leukaemia	Siddarth Nayar
0930	Sensitivity to tetrandrine in vitro treatment is associated with exonic TP53 mutations in acute myeloid leukemia	Daniel Barry
0945	Immuno-flowFISH enables rapid and sensitive detection of chromosome 5 and 7 abnormalities in acute myeloid leukaemia	Tulene Kendrick

0830 - 1000	HSANZ Free Communications: Bone marrow transplant Chairs: Stephanie Clugston and Xiaowen Wu	M6
0830	Improvement in longitudinal survival outcomes in allogeneic transplantation: The impact of quality initiatives	Safia Belbachir
0845	Health resource utilisation and costs of allogeneic hematopoietic stem cell transplantation: An Australian data-linkage study	Nancy Kim
0900	The effectiveness of pre-transplant interventions in ABO mismatched allogeneic stem cell transplant – a single centre review	Xiaowen Wu

...continued overleaf

0915	Measurable cyclophosphamide on day 0 of allogeneic stem cell transplantation adversely impacts graft-versus-host disease and survival outcomes	Rachel Koldej
0930	Long-term outcomes following allogeneic HSCT for severe aplastic anaemia in adults	Ashleigh Scott
0945	Superior outcomes following allogeneic transplant using alemtuzumab-based conditioning for aplastic anaemia: A single-centre experience	Bashar Alani

0830 - 1000	ANZSBT Presidential Symposium <i>Chairs: Anastazia Keegan and Pierre Tiberghien</i>	BelleVue 1
0830	Laboratory grown cord blood-derived red cells display similarities to cord and neonatal red blood cells: Preliminary findings from the HEARTBEAT study	Sara Chiaretti
0845	Deterministic blood group genotyping from variant call files with RBCeq2	Liam McIntyre
0900	Real time AI-enhanced clinical decision support in transfusion medicine: Validation of a model context protocol	Rounak Dubey
0915	Understanding the pathophysiology of the monocyte monolayer assay (MMA): Characterising the inflammatory response to clinically significant antibodies	Isabelle Lightbody
0930	The epidemiology of red cell transfusion in a five-year retrospective cohort of pregnancies in First Nations, regional and remote women of the Northern Territory, Australia	Tina Noutsos
0945	CRISPR/Cas9-mediated homology-directed repair reveals a RHCE* <i>C</i> -associated variant, rs12048617G, enhances both RhD and RhCE antigen expression via a KLF/Sp regulatory motif	Eunike McGowan

0830 - 1000	THANZ Symposium: Adversity in anticoagulation <i>Chairs: Nicola Eaddy and Stephanie P'Ng</i>	River View 4
0830	Management of bleeding associated with FXa-inhibitors	Jean Connors
0900	Comparison of bleeding risk between Rivaroxaban and Apixaban in acute VTE: The COBRRA trial	Vivien Chen
0930	Risk factors and epidemiology of bleeding following initiation of FXa inhibitors: Insights from the AXIOM study	Katherine Creeper

0830 - 1000	Nurses Symposium: Regional and remote <i>(Kindly sponsored by BeOne Medicine)</i> <i>Chairs: Andrew Steele and Katrina Wragg</i>	M2 and 3
0830	Regional haematology services: A road map	Dustin Hall

...continued overleaf

0900	Rural NP experience	Kerin Young
0930	The Myeloma Real Equity Project – improving equity of access to myeloma support and education in regional, rural and remote Australia	Narelle Smith and Lucy Murphy

1000 - 1030	Morning Tea	Exhibition Hall
--------------------	--------------------	------------------------

1030-1200	HSANZ Presidential Symposium <i>Chairs: Adam Bryant and Hui-Peng Lee</i>	Riverside Theatre
1030	Obinutuzumab, Lenalidomide and Venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma (FL): Primary analysis of the phase I/II investigator-initiated LEVERAGE study	Chan Cheah
1045	Sustained benefits of a 6-week telehealth intervention programme for hematopoietic cell transplant survivors – a multi-centre randomized controlled trial	David Ma
1100	Platelet RNA gene expression mirrors fibrosis in myeloproliferative neoplasms	Belinda Guo
1115	Overcoming microenvironment-mediated resistance in precursor B-cell acute lymphoblastic with the novel amino acid degrader cyst(e)inase	Richard Burt
1130	Redox imbalance and chemoresistance in AML: The central role of NRF2 and ROS detoxification	Anita Chopra
1145	Predictive value of extranodal involvement on clinical outcomes and toxicities in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) following CAR-T cell therapy	Safia Belbachir

1030-1200	ANZSBT / ISBT Symposium: Close contact: Blood, risk and the invisible exchange <i>Chairs: José Eduardo Levi and Marion Vermeulen</i>	River View 5
1030	Parvovirus B19 and Hepatitis A: Results of the first months of Australian donation screening and the impact on components for direct transfusion	Veronica Hoad
1100	Characterizations and follow-up study of hepatitis B virus in blood donors with surface antigen positive but DNA negative in southern China	Xianlin Ye
1115	National serosurvey of hepatitis B core antibody in healthy Australian blood donors	Eileen Roulis
1130	Possible risk of psychrotrophic bacteria going undetected during the bacterial screening of platelet concentrates	Moe Kozakai
1145	The characteristics of blood donors at the Timor-Leste National Blood Bank and the proportion of donations positive for transfusion-transmissible infections	Eurosia Amelia Olijie Cham

...continued overleaf

1030-1200	ANZSBT / ISBT Symposium: Transfusion: The cornerstone of supportive care <i>Chairs: Amanda Ormerod and Cynthia So-Osman</i>	BelleVue 1
1030	Oxygen extraction ratios and the future of physiologic transfusion triggers	Aaron Hess
1100	Longitudinal changes in transfusion practice in myelodysplastic syndromes (MDS): A population data-linkage study	Allison Mo
1115	Role of Isohemagglutinin titer in estimation of transfusion needs in post ABO incompatible hematopoietic stem cell transplant recipients – a study from a tertiary cancer care setting in west India	Archana C C
1130	Investigating recent trends in the use of immunoglobulin for haematological conditions in Australia	Vesna Morosin
1145	Canadian rare blood program review: Managing transfusion requirements during pregnancy	Nicole Reike

1030-1200	ANZSBT / ISBT Symposium: The search for the utopian donor <i>Chairs: Mada Badawi and Yuyun Maryuningsih</i>	BelleVue 2
1030	Global challenges of blood donation	Lin Fung
1100	Plateletpheresis procedure induced haematological parameters modifications in healthy donors	Gopal Kumar Patidar
1115	“Does size matter?” - assessing the impact of donor body mass index on apheresis platelet yield and transfusion efficacy in hypo-proliferative thrombocytopenia	Bhavani Thiruppathy
1130	Perspectives of staff on blood donation experiences among people who donate in later life in Australia	Aaron Akpu Philip
1145	Addressing declining blood donation rates among younger generations: Insights from a targeted survey in Taiwan	Tsing-Fen Ho

1030-1200	THANZ Presidential Symposium <i>Chairs: Philip Choi and James McFadyen</i>	River View 4
1030	Protein dynamics of megakaryocyte maturation	Jose Perdomo
1048	Evaluation of a novel BCR::ABL1 tyrosine kinase inhibitor on platelet activation, thrombus formation and thromboinflammatory responses in chronic myeloid leukaemia	Musab Omar
1106	Targeting platelet calcium dysregulation as a potential mechanism for antiplatelet therapies	Yvonne Kong
1124	Cirrhosis severity correlates with reduced fibrin generation and enhanced fibrinolysis	Tengyi Cai

...continued overleaf

1142	Large bore mechanical thrombectomy for intermediate-high risk pulmonary embolism: Efficacy and safety insights from a single centre Australian site	Roy Wong
1030-1200	Nurses Free Communications: 2 <i>Chairs: Louise English and Kerin Young</i>	M2 and 3
1030	Growing and strengthening an emerging haematology unit through reflective clinical debriefing	Elise Toyer
1048	Team storm project: Building leadership skills and team resilience for nursing staff in a busy outpatient cancer centre	Romony Jeans
1106	Implementation of a nurse practitioner model of care in private practice	Meghan Harris
1124	Transforming care delivery: Evolution of a nurse-coordinated bone marrow biopsy service	Victoria Milliken
1142	Shifting paradigms: Implementation of the first paediatric BMT and cellular therapies nurse practitioner role in Australia	Maddie Gilsenan
1200-1330	Lunch	Exhibition Hall
1215-1315	Grifols Lunch Symposia: Navigating arboviral threats to blood safety <i>Chair: Xiaomei Zhi; Speaker: José Eduardo Levi</i> <i>Pre-registration required</i>	BelleVue 2
1215-1315	Werfen Lunch Symposia: From insight to action: Leading change in transfusion practice <i>Speakers: Ramona Chopra, Mark Howard, Rasika Setia</i> <i>Pre-registration required</i>	BelleVue 1
1215-1315	How to get your paper published	M1
1215-1315	THANZ AGM	River View 4
1215-1315	Nurses Members Meeting	M2 and 3
1330-1425	Ruth Sanger Oration <i>Chair: Anastazia Keegan</i>	Riverside Theatre
1330	Ruth Sanger Oration: Immunogenetics – expanding the horizon for transplantation and transfusion?	Rhonda Holdsworth
1430-1600	HSANZ Symposium: Myeloma: Moving immunotherapy into the mainstream <i>Chairs: Cindy Lee and Hasib Sidiqi</i>	Riverside Theatre
1430	Where does carT fit in myeloma therapy?	Tom Martin <i>(Kindly supported by Johnson & Johnson)</i>

...continued overleaf

1500	BiTE in myeloma	Mohammed Mohty
1530	Taking a BiTE while driving CAR-T: Navigating BsAb TCE and CAR-T sequencing in the land down under for RRM	Hang Quach

1430-1600	HSANZ Symposium: New trends and new tricks in transplantation (Kindly sponsored by AstraZeneca) Chairs: Ashish Bajel and Ashleigh Scott	River View 5
1430	Changing trends in transplantation	Mickey Koh
1500	New developments in the therapy of GVHD	Portia Smallbone
1530	Off-the-shelf BKV-CTL therapy in hemorrhagic cystitis and PML	Katy Rezvani

1430-1600	HSANZ Free Communications: Myeloproliferative neoplasms (Kindly sponsored by Incyte) Chairs: James Liang and Zi Yun Ng	M1
1430	Novel genetic aberrations in chronic myeloid leukemia in adolescents and young adults	Priyavadha Balasubramanian
1445	BOD1L1-loss impairs megakaryocyte development in JAK2V617F+ cells	Ryan Collinson
1500	Prevalence of the JAK2 V617F mutation in the peripheral blood of individuals presenting with acute myocardial infarction	David Ross
1515	When not to test JAK2: Real-world JAK2 mutation testing for the investigation of erythrocytosis	Holly Taylor
1530	Survival impact and kinetics of hemoglobin improvement with momelotinib in patients with myelofibrosis and moderate to severe anemia: Post hoc analyses of SIMPLIFY-1 and MOMENTUM	Andrew Perkins
1545	Myeloproliferative neoplasms – predicting progression to acute leukaemia	Wendy Erber

1430-1600	HSANZ Free Communications: Lymphoid malignancy: Basic science Chairs: Rory Bennett and Nicole Wong Doo	M6
1430	Development of a systematic multimodality lymphoma biobank in an era of comprehensive multiomics	Rebecca Nightingale
1445	Determining the prognostic significance of the Ki67 proliferation index in treatment-naïve follicular lymphoma: An Australasian lymphoma and related-diseases registry (LaRDR) study	Eliza Chung
1500	Development of an in vitro biomarker platform for determining bispecific antibody efficacy in haematological malignancies	Rachel Koldej

...continued overleaf

1515	Follicular lymphoma displays distinct gene expression profiles according to histological grade	Allison Baraclough
1530	Does TCR gene re-arrangement still have a role in the diagnosis of T-cell lymphoproliferative disorders? An assessment of assay performance and utility	Thomas Davis
1545	Minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Results from the phase 3 ECHO trial	Chan Cheah

1430-1600	ANZSBT / ISBT Symposium: Plasma...but not as you know it! <i>Chairs: Philip Crispin and Martin Smid</i>	BelleVue 1
1430	FFP for resuscitation of septic shock	Philip Spinella
1500	FFP in the management of burns patients	Elissa Milford
1530	Albumin: Increasing use in the absence of evidence	Nicole Relke

1430-1600	ANZSBT / ISBT Symposium: Transforming transfusion research <i>Chairs: Gwendolyn Clarke and Tina Noutsos</i>	BelleVue 2
1430	Making every drop count: Building a transfusion research team to improve blood use and outcomes	Erica Wood
1500	How do you analyze the effect of red blood cell transfusion on clinical outcome?	Cynthia So-Osman
1530	Value for money matters: Health economic evidence in transfusion research	Adam Irving

1430-1600	THANZ Symposium: Paediatric haemostasis <i>(Kindly sponsored by Novartis)</i> <i>Chairs: Tina Carter and Julie Curtin</i>	River View 4
1430	Paediatric VTE management: Updates from the 2024 ASH/ ISTH guidelines	Carly George
1500	Advances in the management of ITP in children	Melanie Jackson
1530	Dilemmas in paediatric haemophilia	Chris Barnes

1430-1600	THANZ Free Communications: Thrombosis and anticoagulation <i>(Kindly sponsored by Werfen)</i> <i>Chairs: Katherine Creeper and Caroline Dix</i>	M8
1430	FXa inhibitor-related major bleeding (FXIMB) management and outcome in Australia (the FIBROMA Study)	Angela Huang
1445	DOAC usage and outcomes in patients with ESRF or on haemodialysis: Review of local experience	Hadley Bortz

...continued overleaf

1500	Mechanical thrombectomy versus standard anticoagulation alone for iliofemoral deep venous thrombosis: A single-centre retrospective cohort study	Jaiyue (Sophie) Zhong
1515	Real-world management and outcomes of intermediate-risk pulmonary embolism	Julie Wang
1530	Pulmonary embolism and CT pulmonary angiography rates between Māori and Europeans in the Bay of Plenty, New Zealand	Catherine Song
1545	Audit of use of cardiopulmonary bypass (CPB) anti-Xa in the perioperative monitoring of anticoagulation for CPB when baseline activated partial thromboplastin time (APTT) is prolonged	Rose Brailek

1430-1600	Nurses Symposium: Novel therapies <i>Chairs: Marie Condon and Gemma White</i>	M2 and 3
1430	Bispecifics in action: Reprogramming the immune system in haematology	Kelvin Chan
1455	Expanding access to bispecific antibodies: Building a shared-care model across the Mountain West in the United States	Mary Steinbach
1530	Update on clinical trials	Megan Margaria

1600-1630	Afternoon tea	Exhibition Hall
------------------	----------------------	------------------------

1630-1800	HSANZ Symposium: Making a difference in adult ALL <i>(Kindly sponsored by Amgen)</i> <i>Chairs: Georgina Hodges and Matthew Wright</i>	Riverside Theatre
1630	Ph positive ALL; towards a chemotherapy free strategy	Robin Foà
1700	Ph negative adult ALL; the game has changed	Shaun Fleming
1730	MRD in ALL: When and how?	Chun Yew Fong

1630-1800	ANZSBT / ISBT Symposium: Change: For better or worse? <i>Chairs: Amanda Ormerod and Jenny White</i>	River View 5
1630	Responding to an accreditation non-conformance - the pre-transfusion checking process	Clare O'Reilly
1700	Enhancing blood centre operations through lean six sigma methodologies	Rowena Robins
1715	Effect of multi-modal training on knowledge and practices of blood transfusion among nurses working in a tertiary care hospital: A Prospective Interventional study	Siddharth Mittal
1730	Resource constrained settings and high-end technology – strange bedfellows? Implementation of a partially process modelled blood distribution system (BDS) and a 2-year lookback on efficacy and reliability	Dolly Daniel

...continued overleaf

1745	Impact of pathogen reduction on platelet inventory management and refractory investigations	Susan Nahirniak
------	---	-----------------

1630-1800	ANZSBT / ISBT Symposium: Laboratory assessment of platelet immunobiology <i>Chairs: Lin Fung and Nelson Tsuno</i>	BelleVue 1
1630	Platelet immunobiology and TRALI	John-Paul Tung
1700	Deciphering the specific binding profiles of KIR2DL2 with HLA - C molecules using a luminex-based high-throughput assay	Sudan Tao
1715	Mild thrombocytopenia caused by anti-MHC-I compared to anti- α IIb β 3 antibodies in mice	Xiuzhang Xu
1730	Unmasking the gray zone: Five-year discrepancy patterns between SPRCA and ELISA in antiplatelet antibody detection	Shin-Yi Tsai

1630-1800	ANZSBT/ISBT Symposium: Innovative manufacturing techniques for novel blood components of the future <i>Chairs: Jason Acker and Alison Badger</i>	BelleVue 2
1630	Omics and blood quality	Michael Busch (Kindly supported by Roche)
1700	Isolation of young red blood cells for neonatal transfusion using a continuous flow cell separator	Mahsa Yazdanbakhsh
1715	Comparative study on the efficacy of different whole blood filtration methods in leukocyte-depleted blood preparation	Ying Cheng
1730	A new capillary tube method for rapid micro-fractionation of red blood cell subpopulations	Antony Mcnamee
1745	Fractionation of platelet lysates to isolate PF4/CCL5-enriched fractions for neuroregenerative applications	Liling Delila

1630-1800	ANZSBT/ISBT Symposium: Clinical: Patient blood management in action <i>Chairs: Anastazia Keegan and Cynthia So-Osman</i>	M6
1630	Blood health - the future of patient blood management	James Isbister
1700	Red Blood Cell Transfusion in ECMO – A Pilot Feasibility Trial (ROSETTA)	Zoe McQuilten
1715	Implementation of a multi-disciplinary team to deliver a pragmatic patient blood management bundle of care to women with placenta accreta spectrum	Molly Padden

...continued overleaf

1730	Implementation of RHD NIPT screening for group O RhD negative women in pregnancy	Jenni Leverington
1745	Restrictive transfusion practices in MDS - one size may not fit all	Allison Mo
1630-1800	THANZ Symposium: VWF: From physiology to phenotype <i>Chairs: Ross Baker and Chee Wee Tan</i>	River View 4
1630	Regulation of the haemostatic activity of von Willebrand factor	Philip Hogg
1700	Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF	Frank Leebeek
1730	Clinical utility of von Willebrand genetic studies	Huyen Tran
1630-1800	HSANZ / Nurses Joint Symposium: Burnout in health professionals: Understanding and addressing the challenge <i>Chairs: Dustin Hall and Gemma White</i>	M2 and 3
1630	Burnout in the haematology team: What, why and how do we move forward?	Angela Alessandri and Sarah Newman
1800-1930	Poster Viewing	Exhibition Hall
1830-1915	HSANZ Masterclass 1	M1
1830	HR Myeloma, defining and treating an area of unmet need	Gordon Cook
1830-1915	HSANZ Masterclass 2	M6
1830	Frontline therapy of DLBCL	Laurie Sehn
1830-1915	HSANZ Masterclass 3	M8
1830	Can we prevent blood cancer?	Claudia Haerlach and George Vassiliou
1830-1915	Nurses Masterclass	M11
1830	CRS and ICANS in oncology nursing: Advanced assessment and management for immune effector therapies	Mary Steinbach
Please note: Masterclasses are not included in registration fees and are an additional cost. Please see the Registration Desk if you would like to attend.		
1930-2100	GSK Evening Symposia: Anaemia in focus: Evolving strategies in myelofibrosis management <i>Speakers: Andrew Perkins, David Ross, Zi Yun Ng</i> <i>Pre-registration required</i>	Offsite - The Mark

Tuesday 28 October

At a Glance

0700-0815 (pre-registration required)	Lilly Breakfast Symposia: Cut the clutter: CLL <i>River View 5</i>			
	Pfizer Breakfast Symposia: Advancing elranatamab treatment and management strategies for relapsed/refractory multiple myeloma patients in Australian clinical practice <i>River View 4</i>			
0700-0815	Lymphoma and Related Diseases Registry Breakfast Meeting <i>M1</i>		THANZ World Thrombosis Day Walk <i>Meet at Room M6 at 6:55am</i>	
0830-1000	HSANZ Symposium: Mutations and leukaemia biology <i>Riverside Theatre</i> HSANZ Free Communications: Therapeutics in aggressive lymphoma <i>River View 5</i> (Kindly sponsored by Sobi) HSANZ Free Communications: Myeloma: Basic science <i>M6</i>	ANZSBT / ISBT Symposium: Lives on the line: Optimising the management of critically bleeding patients <i>BelleVue 1</i> ANZSBT/ISBT Symposium: Investigating blood groups with genomics: Beware of what lies beneath! <i>BelleVue 2</i>	THANZ Symposium: Bleeding disorders: The near future <i>River View 4</i> (Kindly sponsored by GSK)	Nurses Symposium: Apheresis <i>M2 and 3</i>
1000-1030	Morning Tea <i>Exhibition Hall</i>			
1030-1200	HSANZ Free Communications: Albert Baikie Memorial Medal <i>Riverside Theatre</i> HSANZ Free Communications: Cell therapy in lymphoma <i>River View 5</i>	ANZSBT / ISBT Symposium: Advances in maternal fetal (transfusion) medicine <i>BelleVue 1</i> ANZSBT / ISBT Symposium: Unexpected discoveries from transfusion <i>BelleVue 2</i>	THANZ Free Communications: Haemostasis in health and disease <i>River View 4</i>	Nurses Free Communications 3 <i>M2 and 3</i>
1200-1330	Lunch <i>Exhibition Hall</i>			
Lunchtime sessions: 1215-1315	QuidelOrtho Lunch Symposia: How enzymatic conversion to create universal blood can benefit from the discovery of extended antigens beyond A and B <i>BelleVue 2</i>	Werfen Lunch Symposia: Empowering clinical decision making in transfusion Interventions using best practices in laboratory and point-of-care diagnostics <i>BelleVue 1</i>	HSANZ AGM <i>River View 4</i>	Apheresis Special Practice Network Meeting <i>M2 and 3</i>
1330-1425	Carl de Gruchy Oration: Should haematologists sell their microscopes on eBay? <i>RiversideTheatre</i> <i>Sunderer Juneja</i>			
1430-1600	HSANZ Symposium: Advancing the fight against aggressive lymphoma <i>Riverside Theatre</i> HSANZ Free Communications: Haemolytic anaemia (joint with ANZSBT/ISBT) <i>M1</i> HSANZ Free Communications: Acute lymphoblastic leukaemia <i>M6</i>	QAP Laboratory Haematology <i>River View 5</i>	ANZSBT / ISBT Symposium: Next generation "platelets": Therapeutic potential of platelet lysates and extracellular vesicles <i>BelleVue 1</i> ANZSBT / ISBT Symposium: Top tips for terrific transfusion teaching and training <i>BelleVue 2</i>	THANZ Symposium: New discoveries in thrombotic disorders <i>River View 4</i>
1600-1630	Afternoon Tea <i>Exhibition Hall</i>			
1630-1715	HSANZ Symposium: The great debate: Transplant is dead (or dying) in Ph positive ALL <i>Riverside Theatre</i> HSANZ Symposium: The great debate: The era of stem cell transplantation for myeloma is over <i>River View 5</i>	ANZSBT / ISBT: CMV seronegative blood components - the past, present and future <i>BelleVue 1</i> ANZSBT / ISBT: Early-career transfusion practitioner workshop <i>M1</i> ANZSBT / ISBT: Early-career transfusion scientist workshop <i>M6</i>	THANZ ACS Network: Making hospitals safer <i>River View 4</i>	Nurses Symposium: Panel discussion: The patient comes first: Delivering person-centred, equitable care <i>M2 and 3</i> (Kindly sponsored by Lilly)
1900-late	Gala Dinner & Awards <i>Crown Perth</i>			

Tuesday 28 October

0700-0815	Lilly Breakfast Symposia: Cut the clutter: CLL <i>Speakers: Monique Menzies Wojtowicz and Aaron Sverdlov</i> <i>Pre-registration required</i>	River View 5
0700-0815	Pfizer Breakfast Symposia: Advancing elranatamab treatment and management strategies for relapsed/refractory multiple myeloma patients in Australian clinical practice <i>Chair: Hang Quach; Speaker: Mohamad Mohty</i> <i>Panellists: Phoebe Joy Ho, Wojciech Janowski, Cindy Lee</i> <i>Pre-registration required</i>	River View 4
0830 - 1000	HSANZ Symposium: Mutations and leukaemia biology <i>Chairs: Kern Chai and David Curtis</i>	Riverside Theatre
0830	The causes and consequences of clonal haematopoiesis	George Vassiliou
0900	Hereditary myeloid malignancies in 2025: Strategies for diagnosis and management	Lucy Fox
0930	Advances in molecular characterisation of acute lymphoblastic leukaemia	Rishi Kotecha
0830 - 1000	HSANZ Free Communications: Therapeutics in aggressive lymphoma <i>(Kindly sponsored by Sobi)</i> <i>Chairs: Shane Gangatharan and Dejan Radeski</i>	River View 5
0830	Australian patients with relapsed or refractory diffuse large B-cell lymphoma frequently fail eligibility criteria for landmark and registrational clinical trials	Elizabeth Goodall
0845	Durvalumab and acalabrutinib for relapsed/refractory (r/r) high-grade B-cell lymphoma: MoST15, open label phase II sub-study of the molecular screening and therapeutics in leukaemia and lymphoma	Steven Lane
0900	Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year follow-up of STARGLO (NCT04408638)	Gareth Gregory
0915	Epcoritamab + R-ICE in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) eligible for autologous stem cell transplantation (ASCT): EPCORE NHL-2	Eliza Hawkes
0930	Improved outcomes with CAR-T cell therapy in R/R transformed follicular lymphoma compared to R/R de-novo DLBCL: A single-center experience	Safia Belbachir
0945	Conventional chemotherapy remains effective salvage therapy in relapsed and primary refractory classical Hodgkin lymphoma in the era of novel agents: A single institution experience	Marianne Tan
0830 - 1000	HSANZ Free Communications: Myeloma: Basic science <i>Chairs: Ben Carnley and Angelina Yong</i>	M6

...continued overleaf

0830	Risk factors and modes of progression in solitary bone plasmacytoma with or without minimal marrow involvement	Kenneth Lim
0845	Single cell RNA sequencing and proteomic analysis identifies adipocyte-derived protein which promotes myeloma cell migration in vitro	Laura Trainor
0900	Correlation of undetectable euroflow MRD with induction, maintenance therapy and progression outcomes in real-world multiple myeloma practice	Shin Hnin Wai
0915	Overcoming cereblon species specificity: Development of an IMiD®-sensitive C57BL/KaLwRij murine model of multiple myeloma via CrbnI391V expression	Emma Cheney
0930	Integrative genetic profiling of circulating tumour DNA and bone marrow for multiple myeloma prognostication	Regina Kwarteng
0945	Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real-world evidence of adverse outcomes for high-risk groups	Ghassan Zammar

0830 - 1000	ANZSBT / ISBT Symposium: Lives on the line: Optimising the management of critically bleeding patients <i>Chairs: Anastazia Keegan and Katerina Pavenski</i>	BelleVue 1
0830	Whole blood	Philip Spinella
0900	When VHA reagents change: Implications for critical bleeding	Akmez Latona
0915	Modelling mortality endpoint timing to optimise trial design for haemostatic interventions in traumatic haemorrhage	Zoe McQuilten
0930	Augmentation of the massive transfusion protocol at hospital Tengku Ampuan Rahimah, Malaysia: Cost and care benefits	Anis Zarina
0945	Development of a transfusion risk prediction score model for oncosurgical patients at a tertiary cancer care centre in India	Suryatapa Saha

0830 - 1000	ANZSBT / ISBT Symposium: Investigating blood groups with genomics: Beware of what lies beneath! <i>Chairs: Catherine Hyland and Yanli Ji</i>	BelleVue 2
0830	Importance of investigating serological vs. genetic discrepancies in patients	Genghis Lopez
0900	GP.Nuk: Serological and molecular characterization of a novel MNS hybrid glycophorin	Ploymanee Suwanwootichai
0915	The function analysis of six variations in ABO gene located in the donor splice sites in vitro	Xiaozhen Hong
0930	Revelation of complex RH gene inversion-recombination variant with a novel breakpoint: A molecular mechanism potentially prevalent in Chinese D-- phenotype population	Yanling Ying
0945	Establishment of high-resolution melting analysis for homozygous GYP*MUR allele detection among Thai donors	Onruedee Khantisitthiporn

...continued overleaf

0830 - 1000	THANZ Symposium: Bleeding disorders: The near future <i>(Kindly sponsored by GSK)</i> <i>Chairs: Liane Khoo and Dominic Pepperell</i>	River View 4
0830	Treatment options for von Willebrand disease in the near future	Frank Leebeek
0900	Management of Haemophilia A in 2025 and beyond	Stephanie P'Ng
0930	ADAMTS13 inhibition to treat acquired Von Willebrand Syndrome	Karen Vanhoorelbeke

0830 - 1000	Nurses Symposium: Apheresis <i>Chair: Romony Jeans and Sarah Micucci</i>	M2 and 3
0830	Trading red: The art of getting haematocrit just right in red-cell exchange	Laura Brunt
0850	Targeted leukapheresis: All things calculations	Clair Scott
0910	Thrombotic thrombocytopenic purpura: An apheresis case study	Bridget Hodgkinson
0930	Neuroblastoma and the role of apheresis	Jesper Jensen

1000 - 1030	Morning Tea	Exhibition Hall
--------------------	--------------------	------------------------

1030-1200	HSANZ Free Communications: Albert Baikie Memorial Medal <i>Chairs: Adam Bryant, Hui-Peng Lee and Matthew Wright</i>	Riverside Theatre
1030	A novel structural variant involving ANKRD26 is responsible for severe inherited thrombocytopenia and leukaemia predisposition in an Australian family pedigree	Ahmad Alcheikh
1045	Gene editing of KLF1 to cure sickle cell disease	Stephanie Anderson
1100	Restoring gut health improves outcomes in high-risk ALL in a novel germ-free mouse model	Elyse Page
1115	Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after citacabtagene autoleucel CAR-T in multiple myeloma	Kenneth Lim
1130	Anagrelide is associated with variant allele frequency increases in both CALR- and JAK2 V617F-mutated patients with Myeloproliferative Neoplasms	ZI Yun NG
1145	Longitudinal assessment of the expansion of clonal haematopoiesis of indeterminate potential (CHIP)	Jasmine Singh

1030-1200	HSANZ Free Communications: Cell therapy in lymphoma <i>Chairs: Stephen Boyle and Eliza Hawkes</i>	River View 5
1030	Empowering CAR T-cell therapy patient care through innovative remote patient monitoring: A pilot trial in Western Australia	Tom Buss

...continued overleaf

1045	Real-world experience of Australian patients with transformed follicular lymphoma treated with chimeric antigen receptor T-cell therapy	Shafqat Inam
1100	Chimeric antigen receptor (CAR) T-cell therapy is safely deliverable in an elderly population with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): An Australian multi-centre experience	Mark Dowling
1115	Brexucabtagene autoleucel in adults with relapsed or refractory mantle cell lymphoma or (MCL) B-cell acute lymphoblastic leukaemia (B-ALL): An Australian single-centre prospective study	Sean Harrop
1130	Exploring baseline cognitive function assessments as a predictor of ICANS in CAR-T cell therapy patients	Safia Belbachir
1145	Multicentre, real-world outcome of patients with Richter's transformation receiving chimeric antigen receptor T-cell (CAR T-cell) therapy in Australia	Jian Li

1030-1200	ANZSBT / ISBT Symposium: Advances in maternal fetal (transfusion) medicine <i>Chairs: Gwendolyn Clarke and Anastazia Keegan</i>	BelleVue 1
1030	Implementation of RhD NIPT in Western Australia	Jan Dickinson AM
1100	HDFN/NIPT test development/methodology	Nicole Thornton
1130	HDFN: Global realities and new multidisciplinary practice guidelines for prevention and management	Molly Sherwood

1030-1200	ANZSBT / ISBT Symposium: Unexpected discoveries from transfusion <i>Chairs: Tina Noutsos and Pierre Tiberghien</i>	BelleVue 2
1030	Blood group antigens on other haematopoietic cells	Jill Storry
1100	Emerging pathogens: Contributions of blood donor surveillance to maintain blood safety and inform public health responses	Michael Busch (Kindly supported by Roche)
1130	Big data – the Danish blood donor study	Christian Erikstrup

1030-1200	THANZ Free Communications: Haemostasis in health and disease <i>Chairs: Lisa Kaminskis and Sara Ng</i>	River View 4
1030	Platelet presence impairs viable CD34+ cell yields and quality of transplant products in autologous stem cell harvests	Justin Xia
1045	Haemocompatibility testing of catheter materials in human blood indicates activation of coagulation and haemolysis in the presence of chlorhexidine coatings	Francesco Monti
1100	Plasmin generation assay in predicting arterial thrombotic outcome in patients with chronic kidney disease	Vincent Lu

...continued overleaf

1115	Risk factors for venous thromboembolism in women with placenta accreta spectrum	Nina EL-Ahwany
1130	Age-related global coagulation changes: From birth to old age	Vincent Lu
1145	IV Epoprostenol infusion is safe in MPN associated peripheral ischaemia	George Mason
1030-1200	Nurses Free Communications 3 <i>Chairs: Nicole Gavin and Andrew Steele</i>	M2 and 3
1030	Time to severe immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy: A real-world single-site experience to inform nursing practice	Jemma Stewart
1048	Real-time SCIg infusion tracking: Empowering patients with MyDHR app	Narelle Duncan
1106	Experience with administration of Vyxeos in the inpatient and outpatient setting	Barbara O'Callaghan
1124	Cross-sectional survey of the barriers and enablers to preventing iatrogenic anaemia in inpatients with haematological malignancies	Courtney Black
1142	Cellular therapies in a private hospital setting: A single-centre Australian experience	Mary Sharlyn Benemerito
1200-1330	Lunch	Exhibition Hall
1215-1315	QuidelOrtho Lunch Symposia: How enzymatic conversion to create universal blood can benefit from the discovery of extended antigens beyond A and B <i>Speaker: Martin L. Olsson</i> <i>Pre-registration required</i>	BelleVue 2
1215-1315	Werfen Lunch Symposia: Empowering clinical decision making in transfusion Interventions using best practices in laboratory and point-of-care diagnostics <i>Speaker: Ajay Gandhi</i> <i>Pre-registration required</i>	BelleVue 1
1215-1315	HSANZ AGM	River View 4
1215-1315	Apheresis Special Practice Network Meeting	M2 and 3
1330-1425	Carl de Gruchy Oration <i>Chair: Hui-Peng Lee</i>	Riverside Theatre
1330	Carl de Gruchy Oration: Should haematologists sell their microscopes on eBay?	Surender Juneja

...continued overleaf

1430-1600	HSANZ Symposium: Advancing the fight against aggressive lymphoma <i>Chairs: Allison Barraclough and Katharine Lewis</i>	Riverside Theatre
1430	CarT in large cell lymphoma	Sattva Neelapu <i>(Kindly supported by Gilead)</i>
1500	Advancing therapies for aggressive lymphoma	Laurie Sehn
1530	Richter's lymphoma	Matthew S. Davids <i>(Kindly supported by AbbVie)</i>

1430-1600	HSANZ Free Communications: Haemolytic anaemia (joint with ANZSBT/ISBT) <i>Chairs: Phil Choi and Sumita Ratnasingam</i>	M1
1430	Autoimmune Haemolytic Anaemia – ANZ guideline	Robert Bird
1500	Interim analysis of the ongoing COMPLETE study on the real-world effectiveness of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria (PNH)	Danny Hsu
1515	Renal complications of sickle cell disease in an Australian cohort	Sara Dohrmann
1530	Adherence to best practice management of patients with sickle cell disease presenting to a paediatric emergency department with vaso-occlusive crisis and/or acute chest syndrome	Eyitoritse Mojuetan
1545	High mortality rate of warm autoimmune haemolytic anaemia: Real-world incidence and outcomes from a comprehensive regional Australian audit	Jun Yen Ng

1430-1600	HSANZ Free Communications: Acute lymphoblastic leukaemia <i>Chairs: Sung Kai Chiu and Jamie Kuzich</i>	M6
1430	NGS-based measurable residual disease (MRD) monitoring improves patient outcomes in B-acute lymphoblastic leukaemia (B-ALL)	Meena Nagarethinam
1445	Investigating the role of chemokine-like factor in paediatric B-ALL relapse	Caleb Lill
1500	Modelling the CNS-niche in vitro to investigate therapeutic vulnerabilities in acute lymphoblastic leukaemia	Luke Quinlan
1515	Characterising the role of butyrate, a microbial short-chain fatty acid, in modulating cellular dynamics of acute lymphoblastic leukaemia cell lines	Cate Cheney
1530	Partner matters: The role of the 5' ABL fusion gene in asciminib efficacy	Elias Lagonik
1545	Fertility preservation in people with acute leukaemia: A ten-year retrospective study at a single tertiary Australian centre	Nicole Li

...continued overleaf

1430-1600	QAP Laboratory Haematology <i>Chairs: John Giannoutsos and Surender Juneja</i>	River View 5
1430	QAP Morphology	John Giannoutsos
1500	Current approach to laboratory diagnosis of bone marrow failure syndromes	Lucy Fox
1530	Myeloproliferative neoplasms – morphology of the progressive phase	Wendy Erber

1430-1600	ANZSBT / ISBT Symposium: Next generation "platelets": Therapeutic potential of platelet lysates and extracellular vesicles <i>Chairs: Jason Acker and Nelson Tsuno</i>	BelleVue 1
1430	Platelet EVs	Thierry Burnouf
1450	Extracellular vesicles from platelet concentrates promote olfactory bulb neurogenesis in experimental models	Abinaya Srinivasan
1500	Platelet lysates and extracellular vesicles protect neurons from ferroptosis and mitochondrial damage	Kirti Gupta
1515	Extracellular vesicles derived from platelet cryopreservation are functional: Reducing clotting times and enhancing thrombin generation in vitro	Ben Winskel-Wood
1530	Platelet-rich plasma derived exosomes mitigate inflammation and ferroptosis in knee osteoarthritis chondrocytes	Qing Chen
1545	Extracellular vesicles (EVs) provide an additional source of biological response modifiers (BRMs) in fresh and stored buffy coat platelet concentrates	Lauren Litchfield

1430-1600	ANZSBT / ISBT Symposium: Top tips for terrific transfusion teaching and training <i>Chairs: Maha Badawi and Amanda Catherwood</i>	BelleVue 2
1430	Modernising transfusion medicine teaching (boot camp)	Katerina Pavenski
1500	Essential online learning to assist laboratory scientists to get bench-ready for transfusion	Sarah Kowalski
1515	Introduction of the lifeblood transfusion practitioner certificate: Bridging the education gap for Australian transfusion practitioners	Jo-anne Greaves
1530	Level Up Learning: Transforming Transfusion Education through Gamification	Carolyn Field
1545	A competency-based integrated anemia module in undergraduate medical education: Advancing to step 4, phase A of the WHO patient blood management (PBM) implementation guidance for national health systems	Yashaswi Dhiman

...continued overleaf

1430-1600	THANZ Symposium: New discoveries in thrombotic disorders <i>Chairs: Vivien Chen and Melita Cirillo</i>	River View 4
1430	Decoding autoantibodies in thrombotic anti-PF4 immune disorders	Jing Jing Wang
1500	When immune complexes meet the endothelium: A common thrombotic pathway in HIT and VITT	Freda Passam
1530	CHIP and thrombosis	Jasmine Singh
1430-1600	Nurses Symposium: Future directions in cancer care <i>Chairs: Helena Furdas and Gemma White</i>	M2 and 3
1430	Establish, expand, sustain: The advanced practice nurse in cancer care	Ellen Heywood
1500	Home-based cancer therapy delivery and future directions	Lorna Cook
1530	Update on the Australian cancer plan	Lucy Gent
1600-1630	Afternoon Tea	Exhibition Hall
1630-1715	HSANZ Symposium: The great debate: Transplant is dead (or dying) in Ph positive ALL <i>Chair: Shaun Fleming</i>	Riverside Theatre
1630	Intro	Chair
1635	Transplant is dead (or dying) in Ph positive ALL: Against	Mohamad Mohty
1650	Transplant is dead (or dying) in Ph positive ALL: For	Robin Foà
1630-1715	HSANZ Symposium: The great debate: The era of stem cell transplantation for myeloma is over <i>Chair: Adam Bryant</i>	River View 5
1630	Intro	Chair
1635	The era of stem cell transplantation for myeloma is over: For ASCT	Gordon Cook
1650	The era of stem cell transplantation for myeloma is over: Against ASCT	Tom Martin <i>(Kindly supported by Johnson & Johnson)</i>

...continued overleaf

1630-1715	ANZSBT / ISBT: CMV seronegative blood components - the past, present and future <i>Chair: Philip Crispin and Amanda Ormerod</i>	BelleVue 1
1630	The past	Bryony Ross
1645	The present	James Daly
1700	The future	Philip Crispin
1630-1715	ANZSBT / ISBT: Early-career transfusion practitioner workshop <i>Chair: Rebecca McLean</i>	M1
1630	The role of the practitioner – a Canadian perspective	Clare O' Reilly
1655	Transfusion practitioner networking and resources	Amanda Catherwood
1705	Mentoring opportunities	Rebecca McLean
1630-1715	ANZSBT / ISBT: Early-career transfusion scientist workshop <i>Chair: Alison Badger</i>	M6
1630	Early-career transfusion scientist workshop	Jill Storry and Nicole Thornton
1630-1715	THANZ ACS Network: Making hospitals safer <i>Chair: Hadley Bortz and Ashleigh Lawrence</i>	River View 4
1630	Introduction to THANZ ACS network	Hadley Bortz
1640	Prevalence of inappropriate apixaban prescribing within a single-centre tertiary hospital	Katherine Creeper
1655	Anticoagulation stewardship in cancer care: Implementation and impact on prescribing safety and patient outcomes	Cheryl Jackson
1710	Preventability of venous thromboembolism in hospitalised patients at a quaternary referral and major trauma centre	Harry Kalma
1630-1715	Nurses Symposium: Panel discussion: The patient comes first: Delivering person-centred, equitable care <i>(Kindly sponsored by Lilly)</i> <i>Chairs: Ty Simpson and Gemma White</i>	M2 and 3
1630	Panel discussion: The patient comes first: Delivering person-centred, equitable care	Lorna Cook, Lucy Gent, Cassi Lawrence, Mary Steinbach
1900-late	Gala Dinner and Awards	Crown Perth

Wednesday 29 October

At a Glance

0900-1030	HSANZ Symposium: Fitness and frailty in plasma cell disorders <i>Riverside Theatre</i>	HSANZ Free Communications: CLL <i>M11</i>
	ANZSBT / ISBT Symposium: Neonatal and paediatric transfusion: Little patients, big problems! <i>BelleVue 1</i>	ANZSBT / ISBT Symposium: Where do you see yourself in 5 years? Changes in antenatal transfusion laboratory practice <i>BelleVue 2</i>
	THANZ / HOW Collaborative Symposium: Women's health <i>River View 4</i>	
1030-1100	Morning Tea <i>Exhibition Hall</i>	
1100-1245	Closing Plenary: Future of cellular therapies <i>Riverside Theatre</i>	

Perth Convention and Exhibition Centre



Wednesday 29 October

0900 - 1030	HSANZ Symposium: Fitness and frailty in plasma cell disorders <i>Chairs: Rajeev Rajagopal and Tom Sapsford</i>	Riverside Theatre
0900	Frailty adjusted therapy in myeloma	Gordon Cook
0930	Predicting and managing the side effects of immunotherapies	Tom Martin <i>(Kindly supported by Johnson & Johnson)</i>
1000	Differentiating light chain amyloidosis from the rest	Matt Rees

0900 - 1030	HSANZ Free Communications: CLL <i>Chairs: Xavier Badoux and Gavin Cull</i>	M11
0900	Discovery of a targetable ubiquitin complex (MARCH5:UBE2J2:MFN2) central to therapeutic stress tolerance across diverse haematologic malignancies	Thomas Lew
0915	Anti-CD20 H429F monoclonal antibody with enhanced hexamerisation exhibits potent complement-dependent cytotoxicity when compared to the unmodified monoclonal antibody in chronic lymphocytic leukaemia	On Ki Chan
0930	Detection of prognostically important subgroups in chronic lymphocytic leukaemia using immuno-flowFISH and imaging flow cytometry	Hun Chuah
0945	CD20 antigen loss post-Venetoclax/anti-CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and future implications	Tamasine Stewart
1000	BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus Idelalisib+Rituximab or Bendamustine+Rituximab in BTKi-pretreated CLL/SLL	Minh Hua
1015	The cost of serious infections and immunoglobulin replacement therapy in chronic lymphocytic leukaemia: Evidence from linked Australian data	Sara Carrillo De Albornoz

0900 - 1030	ANZSBT / ISBT Symposium: Neonatal and paediatric transfusion: Little patients, big problems! <i>Chairs: Rebecca McLean and Bryony Ross</i>	BelleVue 1
0900	The need for evidence-based transfusion guidelines for neonatal and paediatric patients	Satyam Arora
0930	Blood transfusions and clinical outcomes in neonates and infants undergoing cardiac surgery with cardiopulmonary bypass – a single-centre prospective study	Sueelyn Van Den Helm
0945	Single site experience with red cell exchange transfusion for children and young people with sickle cell disease	Louise English

...continued overleaf

1000	Identifying biomarkers predictive of bleeding in babies undergoing cardiac surgery with cardiopulmonary bypass using proteomics	Suelyn Van Den Helm
1015	Prevalence and characteristics of irregular antibodies in pediatric hematologic patients at the National Institute of Hematology and Blood Transfusion, Vietnam	Hoang Nga

0900 - 1030	ANZSBT / ISBT Symposium: Where do you see yourself in 5 years? Changes in antenatal transfusion laboratory practice <i>Chairs: Gwen Clarke and Sarah Owen</i>	BelleVue 2
0900	One size doesn't fit all	Nicole Thornton
0930	The changing alloantibody prevalence and profile in pregnancy: A Queensland population study	Katie Gould
0945	Maternal RHD variants and non-invasive prenatal RHD testing at Australian Red Cross Lifeblood	Jacqui Martin
1000	Gestational period and alloantibody titre as dual predictors of intrauterine transfusion frequency: Evidence from a high-volume tertiary unit	Aryabhatta Sadhu
1015	RhD epitope mapping and anti-D investigation of common weak D in Chinese population	Yalin Luo

0900 - 1030	THANZ / HOW Collaborative Symposium: Women's health <i>Chairs: Anastazia Keegan and Giselle Kidson-Gerber</i>	River View 4
0900	Von Willebrand disease and women's health: New insights from the WiN study	Frank Leebeek
0930	Adolescent heavy menstrual bleeding	Jennifer Beale
1000	Hormone associated VTE risk	Jean Connors

1030 - 1100	Morning Tea	Exhibition Hall
--------------------	--------------------	------------------------

1100-1245	Closing Plenary: Future of cellular therapies <i>Chairs: Alison Badger, Annette Neylon and Pierre Tiberghien</i>	Riverside Theatre
1100	Optimizing NK cell engineering for therapeutic efficacy	Katy Rezvani
1130	Cellular therapies: Evolving and future roles of blood banks	Mickey Koh
1200	Targeting antigen-specific B cells in immune TTP	Karen Vanhoorelbeke
1230	HSANZ President's closing statement	Hui-Peng Lee
1235	BLOOD 2026 announcement	2026 Committee
1240	ISBT President's closing statement and 2026 promo	Pierre Tiberghien

ISBT KUALA LUMPUR 2026

June 20-24, 2026

**The 39th International Congress of the ISBT
Kuala Lumpur, Malaysia**

In conjunction with the Malaysian Blood Transfusion Society (MBTS)



International Society
of Blood Transfusion



Save the Date...

Blood 2026



18 – 21 October 2026

Auckland, New Zealand
Tāmaki Makaurau, Aotearoa



The combined Annual Scientific Meeting of the:



HSANZ
Haematology Society of
Australia and New Zealand



ANZSBT
Australian & New Zealand Society of Blood Transfusion



THANZ
Thrombosis & Haemostasis society
of Australia and New Zealand